Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INDICATE
NCT04423211Phase 3Recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Oct 2020
- Primary completion
- Dec 2032
- Countries
- 1
01
Overview
A Phase 3 trial of apalutamide in prostate cancer (PCa), sponsored by ECOG-ACRIN Cancer Research Group. Started Oct 2020; status: recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04423211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04423211.